Implantica strengthens the Management team with new VP QA & RA
Implantica AG (publ) is pleased to announce Juliette Cook will join as VP Quality & Regulatory Affairs in August 2021.
Juliette Cook will head the Quality team at Implantica, having most recently been responsible for Regulatory Affairs for EMEA at Cochlear, an active implantable hearing solutions company. With over 20 years of regulatory affairs experience, she has obtained approvals and access to new markets in over 120 countries. Juliette Cook is also an expert in EU Medical Device Regulation (MDR), regularly presenting and teaching the subject at industry events and conferences. Prior to Cochlear, Juliette Cook was Director of Quality, Clinical & Regulatory Affairs at Rayner Intraocular Lenses Ltd. where she established the QA & RA department. She has an M.Sc. in Biomedical Engineering from University of Durham and obtained a Ph.D. in Materials/Mechanical Engineering from the University of Exeter.
“Juliette’s strong experience in developing regulatory strategies and achieving regulatory approvals in a multitude of countries worldwide is essential to Implantica since we are working on regulatory approval in 30 countries in parallel. I am very pleased to have her join our team.” said Peter Forsell, CEO of Implantica.
For further information, please contact:
Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49
nicole.pehrsson@implantica.com
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
The company's Certified Adviser is FNCA Sweden AB, +46 (0)8 528 00 399, info@fnca.se
The information was sent for publication, through the agency of the contact person set out above, on June 21, 2021 at 09:00 a.m. CET.
About Implantica
Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.